Evolving utility of apremilast in dermatological disorders for off‐label indications
Sign Up to like & getrecommendations! Published in 2022 at "Clinical and Experimental Dermatology"
DOI: 10.1111/ced.15377
Abstract: Apremilast, a small molecule that acts by inhibition of the phosphodiesterase‐4 enzyme, has been approved by the US Food and Drug Administration for the management of psoriatic arthritis, plaque psoriasis and Behçet disease. The drug… read more here.
Keywords: label indications; apremilast; utility apremilast; dermatology ... See more keywords
Off-label indications of aspirin in gynaecology and obstetrics outpatients at two Chinese tertiary care hospitals: a retrospective cross-sectional study
Sign Up to like & getrecommendations! Published in 2022 at "BMJ Open"
DOI: 10.1136/bmjopen-2021-050702
Abstract: Objective To investigate the prevalence of off-label aspirin indications and the level of scientific support for off-label indications of aspirin in gynaecology and obstetrics outpatients. Design A retrospective cross-sectional study. Setting Two tertiary hospitals (a… read more here.
Keywords: label indications; gynaecology obstetrics; indications aspirin; obstetrics ... See more keywords
Evaluating the Use of Dalbavancin for Off-Label Indications
Sign Up to like & getrecommendations! Published in 2022 at "Infectious Disease Reports"
DOI: 10.3390/idr14020032
Abstract: (1) Background: Dalbavancin is a long-acting lipoglycopeptide antibiotic approved for skin and soft-tissue infections. Post-marketing experience suggests dalbavancin is being used for off-label indications that normally require long-term intravenous (IV) antibiotics; however, data assessing this… read more here.
Keywords: label indications; dalbavancin; use dalbavancin; evaluating use ... See more keywords